Drug Trial Radar · NCT07652658
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
359
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Sep 18, 2028
Study completion Sep 18, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Placebo for AZD8965Other
Placebo for AZD8965
AZD8965 low doseDrug
AZD8965 low dose
AZD8965 medium doseDrug
AZD8965 medium dose
AZD8965 high doseDrug
AZD8965 high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24Time frame: at Week 24
Locations
198 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Not yet recruiting
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Loma Linda, California · Not yet recruiting
Research Site
Los Angeles, California · Not yet recruiting
Research Site
Newport Beach, California · Recruiting
Research Site
Sacramento, California · Not yet recruiting
Research Site
Stanford, California · Not yet recruiting
Research Site
Aurora, Colorado · Not yet recruiting
Research Site
Denver, Colorado · Recruiting
Research Site
Ocala, Florida · Withdrawn
Research Site
Weston, Florida · Not yet recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Boise, Idaho · Recruiting
Research Site
Champaign, Illinois · Recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Kansas City, Kansas · Not yet recruiting
Research Site
Lexington, Kentucky · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Detroit, Michigan · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Recruiting
Research Site
Greensboro, North Carolina · Not yet recruiting
Research Site
Cincinnati, Ohio · Not yet recruiting
Research Site
Oklahoma City, Oklahoma · Not yet recruiting
Research Site
Fountain Hill, Pennsylvania · Recruiting
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Charleston, South Carolina · Not yet recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
El Paso, Texas · Recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Burlington, Vermont · Not yet recruiting
Research Site
Richmond, Virginia · Not yet recruiting
Research Site
Alberdi, Argentina · Not yet recruiting
Research Site
Buenos Aires, Argentina · Not yet recruiting
Research Site
Ciudad de Buenos Aires, Argentina · Not yet recruiting
Research Site
Florida, Argentina · Not yet recruiting
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.